OncoMatch

OncoMatch/Clinical Trials/NCT06839001

CRYoablation for Small Tumors As Local Treatment - SIX Trial

Is NCT06839001 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for breast cancer.

Phase 3RecruitingHospital do CoracaoNCT06839001Data as of Jun 2026Location: Brazil

To demonstrate the non-inferiority of cryoablation compared to breast surgery for the local treatment of early-stage breast cancer and to conduct a cost-minimization analysis comparing direct costs between treatments.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: ESR1 expression

Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)

Required: PR (PGR) expression

Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)

Required: HER2 (ERBB2) expression

Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)

Required: HER2 (ERBB2) amplification

FISH report for the ERBB2 gene, if necessary

Required: MKI67 expression

Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)

Prior therapy

No prior treatment (treatment-naive required)

Cannot have received: neoadjuvant systemic therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06839001 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Does this trial require ESR1?

Yes, ESR1 expression is a required biomarker for enrollment.

Does this trial require PGR?

Yes, PGR expression is a required biomarker for enrollment.

Does this trial require ERBB2?

Yes, ERBB2 expression is a required biomarker for enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify